The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors
- PMID: 17587419
- DOI: 10.1111/j.1440-1843.2007.01101.x
The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors
Abstract
Background and objective: To evaluate the characteristics and prognostic factors of Japanese patients with lymphangioleiomyomatosis (LAM).
Methods: A nationwide survey to identify patients with LAM was conducted by questionnaire. Survival probability was estimated using the Kaplan-Meier method, and the prognostic factors were analysed by Cox regression.
Results: Data were collected on 173 patients with pulmonary LAM. The major presenting features were pneumothorax (43%) and exertional dyspnoea (37%). The survival probabilities for patients presenting with exertional dyspnoea (Group A) were 85%, 60% and 47% after 5, 10 and 15 years, respectively, and for patients presenting with pneumothorax (Group B) were 95%, 89% and 89%, respectively. Although the age at symptom onset was higher among patients in Group A than in Group B, Cox regression revealed that the presenting feature was a prognostic factor independent of age at symptom onset (Group A/B hazard ratio = 5.732, P < 0.01). In the subgroup of patients whose initial FEV(1) was >1000 mL, or FEV(1)/FVC >40%, or %DL(CO) >40%, the rate of deterioration in these tests was greater in Group A than in Group B (P < 0.01 for FEV(1), P < 0.05 for FEV(1)/FVC and %DL(CO)).
Conclusions: There are two possible subgroups of LAM patients. One subgroup that presented with pneumothorax, had onset of symptoms at a younger age and a more favourable prognosis; the other presented with exertional dyspnoea, had onset of symptoms at an older age and a poorer prognosis.
Similar articles
-
Emerging clinical picture of lymphangioleiomyomatosis.Thorax. 2005 Oct;60(10):875-9. doi: 10.1136/thx.2004.035154. Epub 2005 Jul 29. Thorax. 2005. PMID: 16055626 Free PMC article.
-
Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.Lung. 2013 Feb;191(1):35-42. doi: 10.1007/s00408-012-9419-3. Epub 2012 Sep 25. Lung. 2013. PMID: 23007140
-
A nationwide survey of lymphangioleiomyomatosis in Korea: recent increase in newly diagnosed patients.J Korean Med Sci. 2010 Aug;25(8):1182-6. doi: 10.3346/jkms.2010.25.8.1182. Epub 2010 Jul 21. J Korean Med Sci. 2010. PMID: 20676330 Free PMC article.
-
Lymphangioleiomyomatosis.Clin Chest Med. 2004 Sep;25(3):573-82, vii. doi: 10.1016/j.ccm.2004.05.003. Clin Chest Med. 2004. PMID: 15331193 Review.
-
Pulmonary lymphangioleiomyomatosis in Korea.Thorax. 1999 Jul;54(7):618-21. doi: 10.1136/thx.54.7.618. Thorax. 1999. PMID: 10377208 Free PMC article. Review.
Cited by
-
Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):206-212. doi: 10.36141/svdld.v35i3.6321. Epub 2018 Apr 28. Sarcoidosis Vasc Diffuse Lung Dis. 2018. PMID: 32476904 Free PMC article.
-
Gene mutations in sporadic lymphangioleiomyomatosis and genotype-phenotype correlation analysis.BMC Pulm Med. 2022 Sep 18;22(1):354. doi: 10.1186/s12890-022-02154-0. BMC Pulm Med. 2022. PMID: 36117164 Free PMC article.
-
Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.Clin Epidemiol. 2015 Apr 7;7:249-57. doi: 10.2147/CLEP.S50780. eCollection 2015. Clin Epidemiol. 2015. PMID: 25897262 Free PMC article. Review.
-
Lymphatic involvement in lymphangioleiomyomatosis.Ann N Y Acad Sci. 2008;1131:206-14. doi: 10.1196/annals.1413.018. Ann N Y Acad Sci. 2008. PMID: 18519973 Free PMC article. Review.
-
Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Respir Med. 2010 Jul;104 Suppl 1(Suppl 1):S45-58. doi: 10.1016/j.rmed.2010.03.017. Respir Med. 2010. PMID: 20630348 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources